Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
FGF2 induces breast cancer growth through ligand-independent activation and recruitment of ERα and PRBΔ4 isoform to MYC regulatory sequences.
Giulianelli S, Riggio M, Guillardoy T, Pérez Piñero C, Gorostiaga MA, Sequeira G, Pataccini G, Abascal MF, Toledo MF, Jacobsen BM, Guerreiro AC, Barros A, Novaro V, Monteiro FL, Amado F, Gass H, Abba M, Helguero LA, Lanari C. Giulianelli S, et al. Among authors: abascal mf. Int J Cancer. 2019 Oct 1;145(7):1874-1888. doi: 10.1002/ijc.32252. Epub 2019 Mar 28. Int J Cancer. 2019. PMID: 30843188
Progesterone receptor isoform ratio dictates antiprogestin/progestin effects on breast cancer growth and metastases: A role for NDRG1.
Abascal MF, Elia A, Alvarez M, Pataccini G, Sequeira G, Riggio M, Figueroa V, Lamb CA, Rojas PA, Spengler E, Martínez-Vazquez P, Burruchaga J, Liguori M, Sahores A, Wargon V, Molinolo A, Hewitt S, Lombes M, Sartorius C, Vanzulli SI, Giulianelli S, Lanari C. Abascal MF, et al. Int J Cancer. 2022 May 1;150(9):1481-1496. doi: 10.1002/ijc.33913. Epub 2022 Jan 13. Int J Cancer. 2022. PMID: 34935137
Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial.
Elía A, Saldain L, Vanzulli SI, Helguero LA, Lamb CA, Fabris V, Pataccini G, Martínez-Vazquez P, Burruchaga J, Caillet-Bois I, Spengler E, Acosta Haab G, Liguori M, Castets A, Lovisi S, Abascal MF, Novaro V, Sánchez J, Muñoz J, Belizán JM, Abba MC, Gass H, Rojas P, Lanari C. Elía A, et al. Among authors: abascal mf. Clin Cancer Res. 2023 Mar 1;29(5):866-877. doi: 10.1158/1078-0432.CCR-22-2060. Clin Cancer Res. 2023. PMID: 36269797 Free PMC article.
Isoform specificity of progesterone receptor antibodies.
Fabris V, Abascal MF, Giulianelli S, May M, Sequeira GR, Jacobsen B, Lombès M, Han J, Tran L, Molinolo A, Lanari C. Fabris V, et al. Among authors: abascal mf. J Pathol Clin Res. 2017 Oct 10;3(4):227-233. doi: 10.1002/cjp2.83. eCollection 2017 Oct. J Pathol Clin Res. 2017. PMID: 29085663 Free PMC article.
E-cadherin: A determinant molecule associated with ovarian cancer progression, dissemination and aggressiveness.
Rosso M, Majem B, Devis L, Lapyckyj L, Besso MJ, Llauradó M, Abascal MF, Matos ML, Lanau L, Castellví J, Sánchez JL, Pérez Benavente A, Gil-Moreno A, Reventós J, Santamaria Margalef A, Rigau M, Vazquez-Levin MH. Rosso M, et al. Among authors: abascal mf. PLoS One. 2017 Sep 21;12(9):e0184439. doi: 10.1371/journal.pone.0184439. eCollection 2017. PLoS One. 2017. PMID: 28934230 Free PMC article.